Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| IXHL | Incannex Healthcare | $3.69 | -$2.28 | -38.19% | 95.9K | $69M | $2.40$49.80 |
| ACXP | Acurx Pharmaceuticals | $4.47 | -$1.56 | -25.87% | 5.3M | $15M | $1.33$21.00 |
| NOA | North American Construction Group | $12.54 | -$4.21 | -25.13% | 20.3K | $479M | $12.12$18.24 |
| SST | System1 | $1.95 | -$0.58 | -22.93% | 54.3K | $21M | $1.95$15.00 |
| ZNB | Zeta Network Group | $8.35 | -$2.44 | -22.59% | 49.4K | $1.6B | $7.52$2,800.00 |
| NTSK | Netskope | $9.41 | -$2.72 | -22.42% | 15.5M | $4.8B | $8.81$27.99 |
| RPID | Rapid Micro Biosystems | $3.40 | -$0.98 | -22.37% | 6.8K | $194M | $1.86$4.94 |
| SRI | Stoneridge | $5.99 | -$1.67 | -21.80% | 749.1K | $215M | $3.54$9.71 |
| SEV | Aptera Motors | $2.72 | -$0.71 | -20.70% | 1.4M | $111M | $1.29$40.85 |
| RHLD | Resolute Management | $121.93 | -$31.75 | -20.66% | 6.2K | $1.3B | $24.22$236.19 |
| PLYX | Polaryx Therapeutics | $4.59 | -$1.17 | -20.31% | 742.6K | $273M | $2.20$48.91 |
| AGCC | Agencia Comercial Spirits | $15.00 | -$3.69 | -19.74% | 20.9K | $642M | $3.66$24.98 |
| CRMT | America's Car-Mart | $15.57 | -$3.48 | -18.27% | 13K | $158M | $14.58$62.72 |
| GEMG | Themes ETF Trust - Leverage Shares 2x Long Gemi Daily ETF | $2.06 | -$0.44 | -17.61% | 130.4K | - | $1.13$17.73 |
| KLXE | KLX Energy Services | $2.44 | -$0.51 | -17.29% | 388.9K | $53M | $1.46$4.84 |
| AMCI | Amc Robotics | $7.88 | -$1.57 | -16.61% | 119.6K | $214M | $2.50$42.00 |
| SXTP | 60 Degrees Pharmaceuticals | $2.69 | -$0.53 | -16.38% | 4.4M | $3.4M | $1.36$17.68 |
| WTF | Waton Financial | $3.10 | -$0.60 | -16.22% | 62.6K | $176M | $2.71$19.85 |
| FGL | Founder Group | $5.30 | -$1.02 | -16.14% | 26K | $107M | $5.15$155.00 |
| OIO | Esgl | $3.15 | -$0.59 | -15.78% | 140 | $156M | $1.63$4.32 |
| IPX | IperionX | $41.85 | -$7.76 | -15.64% | 15K | $1.7B | $12.28$61.45 |
| KEQU | Kewaunee Scientific | $35.00 | -$5.98 | -14.59% | 1.7K | $117M | $30.33$60.89 |
| PSNL | Personalis | $6.81 | -$1.14 | -14.34% | 68.6K | $832M | $2.83$11.50 |
| FHTX | Foghorn Therapeutics | $4.86 | -$0.79 | -13.98% | 7.3K | $331M | $2.94$6.95 |
| VEON | Veon | $45.90 | -$7.38 | -13.85% | 198.1K | $3.7B | $34.55$64.00 |
| ADPT | Adaptive Biotechnologies | $12.26 | -$1.96 | -13.78% | 109.1K | $2.2B | $6.68$20.76 |
| KMLI | KraneShares 2x Long Meli Daily ETF | $8.62 | -$1.34 | -13.48% | 139.4K | - | $8.50$29.70 |
Related Articles
Featured Article
Cathie Wood Is Loading Up on These 3 Small-Cap Stocks: Should You?
Keith Speights|Dec 12, 2023
The Ark Invest founder sees potential in these three under-the-radar stocks.
ASCO 2022: Surprising News in Cancer Research
Taylor Carmichael and Patrick Bafuma|Jun 10, 2022
The American Society of Clinical Oncology (ASCO) just finished up its annual meeting. We have some winners coming out of the conference.
10 Amazing Stocks Under $10 (Part II)
Taylor Carmichael|May 13, 2022
Because of this stock market crash, some wonderful stocks are super cheap in 2022. Here's a mini-portfolio of innovative companies trading under $10 a share right now.
Cathie Wood Can't Get Enough of These 2 Biotech Stocks
Cory Renauer|Mar 31, 2022
The CEO of Ark Invest hasn't given up on these risky biotech stocks.
Cathie Wood Goes Dumpster Diving: 3 Beaten Down Stocks She Just Bought
Cory Renauer|Sep 9, 2021
All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.
3 Life Science Stocks Cathie Wood's Buying Hand Over Fist Right Now
Cory Renauer|Aug 15, 2021
ARK Invest made multiple purchases of these stocks last week.
If You Invested $10,000 in Personalis in the Coronavirus Crash, This Is How Much You'd Have Now
Taylor Carmichael|Jan 23, 2021
Investors weren't very happy when shares tanked in March, but have been smiling ever since.
5 Under-the-Radar Tickers That Will Stomp the Market in 2021
Taylor Carmichael|Nov 19, 2020
Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.
Personalis Turns to Liquid Biopsies for Growth. Will It Work?
Maxx Chatsko|Aug 14, 2020
The company, which leans on one customer for 76% of revenue, desperately needs to diversify its customer base.
Is Adaptive Biotechnologies a Buy?
Cory Renauer|Jul 30, 2020
Does this unusual biotech stock have what it takes to deliver market-beating gains?
